https://www.nmdpharma.com/news daily 0.75 2026-03-11 https://www.nmdpharma.com/news/oral-presentation-mda-conference monthly 0.5 2026-03-11 https://www.nmdpharma.com/news/nmd-pharma-posters-at-mda-conference-2026 monthly 0.5 2026-03-11 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/9d27b694-fb5c-4545-aa35-e86c3d6bf917/250310_PR_MDA_Downloads+for+website_2.jpg News - Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference 2026 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.nmdpharma.com/news/nmd-pharma-synpase-cmt-phase-2a-clinical-study-data-accepted-for-late-breaking-oral-presentation-at-2026-mda-scientific-amp-medical-conference monthly 0.5 2026-02-17 https://www.nmdpharma.com/news/topline-results monthly 0.5 2026-02-03 https://www.nmdpharma.com/news/jp-morgan-nmdpharma-presentation monthly 0.5 2026-02-06 https://www.nmdpharma.com/news/jp-morgan-healthcare-conference-2026 monthly 0.5 2026-01-07 https://www.nmdpharma.com/news/cmoanadevera monthly 0.5 2025-09-03 https://www.nmdpharma.com/news/10-year-anniversary monthly 0.5 2025-05-29 https://www.nmdpharma.com/news/pr-mgfa monthly 0.5 2025-05-13 https://www.nmdpharma.com/news/press-release-250325 monthly 0.5 2025-03-25 https://www.nmdpharma.com/news/rdd2025 monthly 0.5 2025-03-03 https://www.nmdpharma.com/news/fda-orphan-drug-designation monthly 0.5 2025-01-09 https://www.nmdpharma.com/news/nmd-pharma-announces-publication-of-phase-1-clinical-trial-data-evaluating-nmd670-in-healthy-volunteers-in-the-journal-clinical-pharmacology-therapeutics monthly 0.5 2024-12-20 https://www.nmdpharma.com/news/nmd-pharma-publishes-paper-in-annals-of-clinical-and-translational-neurology monthly 0.5 2024-12-18 https://www.nmdpharma.com/news/ecmtf-webinar monthly 0.5 2024-12-10 https://www.nmdpharma.com/news/nmd-pharma-initiates-phase-2-study-of-nmd670-in-patients-with-cmt-type-1-and-2 monthly 0.5 2024-11-18 https://www.nmdpharma.com/news/nmd-pharma-to-present-data-on-aanem-annual-meeting monthly 0.5 2024-10-11 https://www.nmdpharma.com/news/cmt-establish1-zfjpr-wtwwk-ede2a monthly 0.5 2024-07-11 https://www.nmdpharma.com/news/nmd-pharma-receives-ind-clearance-from-the-fda-to-initiate-a-phase-2-clinical-trial-of-nmd670-in-cmt-disease-in-the-us monthly 0.5 2024-06-18 https://www.nmdpharma.com/news/nmd-pharma-initiates-phase-2b-trial-of-nmd670-in-generalized-myasthenia-gravis-patients monthly 0.5 2024-06-11 https://www.nmdpharma.com/news/cure-sma-clinical-trial-update-webinar monthly 0.5 2024-12-09 https://www.nmdpharma.com/news/nmd-pharma-receives-ind-clearance-for-phase-2-clinical-trial-of-nmd670 monthly 0.5 2024-06-10 https://www.nmdpharma.com/news/pr-science-translational-medicine monthly 0.5 2024-03-21 https://www.nmdpharma.com/news/comprehensive-data-package-for-nmd670-in-science-translational-medicine monthly 0.5 2024-03-21 https://www.nmdpharma.com/news/international-womens-day-sabine-from-jeito monthly 0.5 2024-03-08 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1709894577225-8JYCTYH33ABOHFAO1F6T/IWD_Sabine_Jeito_600x400.jpg News - International Women’s Day 2024 – “My wish for Women: Dare and just go for it” – Sabine Dandiguian, Managing Partner, Jeito, shares her inspiring journey https://www.nmdpharma.com/news/international-womens-day-thomashp monthly 0.5 2024-03-08 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1709893464518-4YBCDJO3143671MX48N7/IWD_GROUP+and+THP_600x400.jpg News - International Women’s Day 2024 – Celebrating all the incredible women at NMD Pharma https://www.nmdpharma.com/news/presentations-on-skeletal-muscle-targeted-clc-1-therapy monthly 0.5 2024-03-04 https://www.nmdpharma.com/news/morten-bull monthly 0.5 2024-01-22 https://www.nmdpharma.com/news/series-b-financing monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/nmd-to-present-nmd670-clinical-data monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/nmd-initiates-phase-2-trial-of-nmd670-in-sma monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/satellite-symposium-and-clinical-data-at-the-ana monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/smaawarenessmonth monthly 0.5 2023-08-14 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1692048851242-8YE1RQJ2FXZY6932G0YN/SMA+Insight+Claus+Jessen_600x400.jpg News - Spinal Muscular Atrophy (SMA) Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with</a> Claus https://www.nmdpharma.com/news/cure-sma-2023 monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/cmt-establish2 monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/cmt-establish1 monthly 0.5 2023-06-16 https://www.nmdpharma.com/news/danielbrennan1 monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/nmd1343news monthly 0.5 2023-05-25 https://www.nmdpharma.com/news/bioequityeurope2023 monthly 0.5 2023-05-11 https://www.nmdpharma.com/news/bio-europe-spring2023 monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/rarediseaseday2023 monthly 0.5 2024-08-07 https://www.nmdpharma.com/news/jpmorgan2023 monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/mike-heffernan-chairman monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/ind-clearance-sma-type-3 monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/nordic-american-life-science-conference-2022 monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/international-day-of-disabilities monthly 0.5 2022-12-09 https://www.nmdpharma.com/news/ey2022 monthly 0.5 2023-08-01 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/2b81e342-b3ef-4d20-8b99-2b9dfb5413f2/52521714402_3f04603782_o_web.jpg News - We have been awarded Entrepreneur of the Year in the Life Sciences category by EY</a> Denmark! - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.nmdpharma.com/news/synapse-2022 monthly 0.5 2023-08-03 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/f830a996-e519-47ce-a3f9-be524bb4ea66/IMG_7198_web.jpg News - NMD Pharma will be at the Life Science Career Fair Aarhus 22 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.nmdpharma.com/news/bio-europe-2022 monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/top-line-data-nmd670 monthly 0.5 2024-08-07 https://www.nmdpharma.com/news/nmd670-top-line-data monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/blog-skabelon-y8pz6-9x5tr-9t6ea-2jjdf monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/oddfornmd670 monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/globalcmt2022 monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/incubaaward2022 monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/lsx2022 monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/cmtawarenessus2022 monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/icfsr-2022-symposium-4-part-1 monthly 0.5 2024-08-07 https://www.nmdpharma.com/news/icfsr-2022-symposium-4-part-2 monthly 0.5 2024-08-07 https://www.nmdpharma.com/news/icfsr-2022-symposium-4-part-2-8554c monthly 0.5 2024-08-07 https://www.nmdpharma.com/news/icfsr-2022-symposium-4-part-4 monthly 0.5 2024-08-07 https://www.nmdpharma.com/news/edenkent monthly 0.5 2022-08-08 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/66eb0908-0bef-4dae-bb7d-d8ab4b1ade6a/Eden_Kent.jpg News - Spinal Muscular Atrophy (SMA) Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Eden https://www.nmdpharma.com/news/life-of-a-research-scientist-at-nmd-pharma monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/an-active-future monthly 0.5 2024-08-07 https://www.nmdpharma.com/news/icnmd2022 monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/mginterviewulrik monthly 0.5 2023-03-09 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/95f369ff-d5b0-4c0f-86a8-0bb4af683916/Insights_MG+Interview_Ulrik_600x400_.jpg News - Myasthenia Gravis Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Ulrik https://www.nmdpharma.com/news/curesma2022 monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/mginterviewsofie monthly 0.5 2022-06-16 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1655373316973-SFB3MU97MYB9WFPVQXO7/Insights_MG+Interview_01_600x400.jpg News - Myasthenia Gravis Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Sofie - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.nmdpharma.com/news/bio2022 monthly 0.5 2022-07-04 https://www.nmdpharma.com/news/bioequity2022 monthly 0.5 2022-07-04 https://www.nmdpharma.com/news/jorgequiroz monthly 0.5 2022-05-10 https://www.nmdpharma.com/news/usoffice monthly 0.5 2022-05-03 https://www.nmdpharma.com/news/danskerhverv monthly 0.5 2022-05-03 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/478b57e8-a7bb-4aef-806f-2375b0b06760/DanskErhverv_600x400.jpg News - NMD Pharma meets with the Danish Chamber of Commerce Our CEO, Thomas Holm Pedersen and COO, Thomas Kongstad Petersen met with CEO Brian Mikkelsen and Chief Consultant Morten Engsbye from The Danish Chamber of Commerce https://www.nmdpharma.com/news/icfsr2022 monthly 0.5 2022-05-03 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/cf0cf62f-2ecc-4e0a-b786-2a90c1a32c3e/ICFSR_2022_600x400_2.jpg News - We will be taking part in the ICFSR conference Our CEO, Thomas Holm Pedersen is here together with professor William David Arnold and our Clinical Trial Manager, Thomas Skjærlund Grønnebæk https://www.nmdpharma.com/news/dkbio2022 monthly 0.5 2022-05-03 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/90242c01-9cbd-4c0c-aaee-f254906f1e76/DKBIO_600x400_2.jpg News - NMD Pharma will be attending DKBIO</a>&nbsp; https://www.nmdpharma.com/news/nmdpharma-danish-biotek monthly 0.5 2022-03-21 https://www.nmdpharma.com/news/sachs5th monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/davidevans monthly 0.5 2022-03-03 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/9c351161-05ff-4930-8b00-d038851c0f20/David+Evans.jpg News - Welcome to David Evans https://www.nmdpharma.com/news/sabinedandiguian monthly 0.5 2022-03-03 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/6050d08e-19d9-4b2b-a129-036359de47cd/Sabine_Dandiguian.jpg News - Welcome to Sabine Dandiguian https://www.nmdpharma.com/news/new-investor monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/bio-partnering-at-jpm monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/nmd-initiates-establish-study monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/thefirstdose monthly 0.5 2024-01-18 https://www.nmdpharma.com/news/dr-geert-jan-interview monthly 0.5 2022-06-16 https://www.nmdpharma.com/news/nmd-pharma-initiates-an-observational-pilot-study monthly 0.5 2021-08-30 https://www.nmdpharma.com/news/muscular-chloride-channel-inhibition-improves-neuromuscular-function monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/sachs-4th-annual-neuroscience-innovation-forum monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/the-first-oligonucleotides-for-cns monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/aarhus-biotech-company-takes-up-the-fight-against-neuromuscular-diseases monthly 0.5 2023-08-03 https://www.nmdpharma.com/news/nmd-pharma-to-present-at-neuromuscular-drug-development-summit monthly 0.5 2021-08-30 https://www.nmdpharma.com/news/nmd-pharma-moves-corporate-headquarters-to-incuba-to-support-future-growth monthly 0.5 2021-08-30 https://www.nmdpharma.com/news/nmd-pharma-receives-grant-from-the-innovation-fund-denmark monthly 0.5 2021-08-30 https://www.nmdpharma.com/news/nmd-pharma-to-present-at-the-credit-suisse-29th-annual-virtual-healthcare-conference monthly 0.5 2021-08-30 https://www.nmdpharma.com/news/nmd-pharma-initiates-a-combined-phase-i-ii monthly 0.5 2021-08-30 https://www.nmdpharma.com/news/nmd-pharma-is-pleased-to-announce monthly 0.5 2021-08-30 https://www.nmdpharma.com/news/new-bod-members monthly 0.5 2021-08-30 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1619033511532-QQGE0QVB5TNDNW0THZGJ/200527_New+BoD+members.jpg News - Welcome to Monique Schiersing and Roel Bulthuis as new BoD members https://www.nmdpharma.com/news/prominent-canadian-researcher-in-denmark-why-i-left-a-top-job-in-california monthly 0.5 2021-08-30 https://www.nmdpharma.com/news/nmd-pharma-picked-as-biotech-of-the-week-by-labiotecheu monthly 0.5 2021-08-30 https://www.nmdpharma.com/news/nmd-pharma-raises-38m-usd-47-million-series-a-financing monthly 0.5 2021-08-30 https://www.nmdpharma.com/news/category/Press+release monthly 0.5 https://www.nmdpharma.com/news/category/Insights monthly 0.5 https://www.nmdpharma.com/news/category/Events monthly 0.5 https://www.nmdpharma.com/news/category/Other+news monthly 0.5 https://www.nmdpharma.com/press-releases-test daily 0.75 2021-07-07 https://www.nmdpharma.com/press-releases-test/blog-post-title-one-glt46 monthly 0.5 2020-08-25 https://www.nmdpharma.com/press-releases-test/blog-post-title-two-rhdat monthly 0.5 2020-05-20 https://www.nmdpharma.com/press-releases-test/blog-post-title-three-m4ajk monthly 0.5 2020-05-20 https://www.nmdpharma.com/press-releases-test/blog-post-title-four-lkbtn monthly 0.5 2020-05-20 https://www.nmdpharma.com/other-news-test daily 0.75 2021-07-07 https://www.nmdpharma.com/other-news-test/blog-post-title-one-pkgct monthly 0.5 2020-08-25 https://www.nmdpharma.com/other-news-test/blog-post-title-two-d6gba monthly 0.5 2020-05-20 https://www.nmdpharma.com/other-news-test/blog-post-title-three-h6msl monthly 0.5 2020-05-20 https://www.nmdpharma.com/other-news-test/blog-post-title-four-g8zwy monthly 0.5 2020-05-20 https://www.nmdpharma.com/blog-2 daily 0.75 2021-08-04 https://www.nmdpharma.com/blog-2/blog-post-title-one-ngaft monthly 0.5 2022-06-16 https://www.nmdpharma.com/blog-2/blog-post-title-two-td9e8 monthly 0.5 2020-05-20 https://www.nmdpharma.com/blog-2/blog-post-title-three-mcnel monthly 0.5 2020-05-20 https://www.nmdpharma.com/blog-2/blog-post-title-four-4tat2 monthly 0.5 2020-05-20 https://www.nmdpharma.com/blog-2-1 daily 0.75 2021-08-04 https://www.nmdpharma.com/blog-2-1/blog-post-title-one-79ttg monthly 0.5 2021-08-05 https://www.nmdpharma.com/blog-2-1/blog-post-title-two-cla5n monthly 0.5 2021-08-05 https://www.nmdpharma.com/blog-2-1/blog-post-title-three-b9h7m monthly 0.5 2020-05-20 https://www.nmdpharma.com/blog-2-1/blog-post-title-four-wg6th monthly 0.5 2020-05-20 https://www.nmdpharma.com/blog-2-2 daily 0.75 2021-08-05 https://www.nmdpharma.com/blog-2-2/blog-post-title-one-2my6t monthly 0.5 2021-08-30 https://www.nmdpharma.com/blog-2-2/blog-post-title-two-ty4nx monthly 0.5 2020-05-20 https://www.nmdpharma.com/blog-2-2/blog-post-title-three-3nr5a monthly 0.5 2020-05-20 https://www.nmdpharma.com/blog-2-2/blog-post-title-four-s2afh monthly 0.5 2020-05-20 https://www.nmdpharma.com/blog-2-2/category/Test-scientific monthly 0.5 https://www.nmdpharma.com/testside daily 0.75 2021-08-17 https://www.nmdpharma.com/testside/blog-post-title-one-h5hg8 monthly 0.5 2020-08-25 https://www.nmdpharma.com/testside/blog-post-title-two-jga3n monthly 0.5 2020-05-20 https://www.nmdpharma.com/testside/blog-post-title-three-n89pe monthly 0.5 2020-05-20 https://www.nmdpharma.com/testside/blog-post-title-four-wdyhz monthly 0.5 2020-05-20 https://www.nmdpharma.com/new-page daily 1.0 2026-03-24 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/5cfbfbf8-28d3-47fd-b910-6ce3921522be/EOY_Logo_TM.gif https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1da64318-7d12-40a7-9696-8788c64cf10c/IncubaSTARTUP2022.gif https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/b7e662ac-3e1b-4c8c-965b-3fa67d640cfb/00_2025-05-25-NMD_MOLS-8868_small.jpg Home - About us We are a team of more than 60 employees with expertise in all areas of drug development. We are headquartered in Aarhus, Denmark, and collaborate with internationally renowned companies and key opinion leaders in the field of neuromuscular diseases. Learn more https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/0bb04336-7355-4abd-8b27-464f8d822867/Pipeline_1000x750_V5.jpg Home - Pipeline We are working to develop novel small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels that can be applied to a large range of clinical indications and orphan human diseases. https://www.nmdpharma.com/pipeline daily 0.75 2026-03-24 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/72607d62-29e2-426a-a511-4b366d2452e2/Pipeline_plain_1000x_V10.jpg Pipeline https://www.nmdpharma.com/about-nmd-pharma daily 0.75 2026-03-24 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652862152118-2HQ1O10PKR27STMXGW0T/Values_WEB_Passionate+about+Movement.jpg About NMD Pharma https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652862366358-RHY2AJKTUAUQFYZ7H1K1/Values_WEB_Innovate+to+Evolve.jpg About NMD Pharma https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652862402959-KLAEYX2YL54XCCA4H444/Values_WEB_Inspired+by+Resilience.jpg About NMD Pharma https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652862428272-KYFXQAP7Z4VF0109V8GI/Values_WEB_Support+and+Challenge.jpg About NMD Pharma https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/5cfbfbf8-28d3-47fd-b910-6ce3921522be/EOY_Logo_TM.gif https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1da64318-7d12-40a7-9696-8788c64cf10c/IncubaSTARTUP2022.gif https://www.nmdpharma.com/investors daily 0.75 2024-08-07 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/2f328e07-8bcf-4e06-b2dc-459fc1754b14/Inkef+Capital.jpg Investors https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1616064086422-7ZFYW2XJONWHU9T5EEB5/novo.jpg Investors https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/d109ceca-958c-491f-be2f-37456ed3b7a8/Roche.jpg Investors https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1616066635989-WBRKKWERQKEY9VNYP5DZ/Lundbeck+Fonden.jpg Investors https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/daaa772e-675c-49ee-9f96-146616514442/Jeito.jpg Investors https://www.nmdpharma.com/contact daily 0.75 2026-03-24 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/a1a5ecb3-a689-4b5c-9672-abc4cc9d212e/NMD_contact.png Contact - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/8a315744-dbff-4671-8c0a-92621d2fe95c/2022_Contact_map.jpg Contact https://www.nmdpharma.com/careers daily 0.75 2026-02-24 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/0c0805e2-3609-4c8e-a2a4-76cbf43fb3d7/240807_Michael_4_500x500.jpg Your career Michael Voldsgaard Clausen Senior Research Scientist https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/55611caf-9e94-4434-8098-20aed1c05c7f/240312_Katja_Krustrup_Pedersen_1000x.jpg Your career Katja Krustrup Pedersen Non-clinical Administrator https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/d286b8fe-0301-4bc3-9663-8a035ca5d1ef/230315_Jeppe-Blichfeldt-Winther_500x500.jpg Your career Jeppe Blichfeldt Winther Research Scientist https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/9afa5fb0-2309-4c4f-8335-2928260f6a31/230103_Marianne_Skals_alt_500x500.jpg Your career Marianne Skals Manager, Pharmacology https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/35fc8e25-d576-4517-9018-9edca07f7228/Tina_Lohmann_500x500.jpg Your career Tina Lohmann Veterinary Nurse and Laboratory Technician https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1634294902263-RG2J66A1YLV58AJKVE9J/2021-09-29-NMD8749_500x500.jpg Your career Kamilla Løhde Dybdahl Research Scientist https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1634294932593-O8Q4IWTH51JBEWH9ZZG1/2021-03-08-NMD-2964_TSG_500x500_NY.jpg Your career Thomas Skjærlund Grønnebæk Principal Scientist https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1615505881035-Q7B4M3AT7N7QRMH4019S/Udklip_layout8.JPG Your career - “Enable better lives through novel therapies to restore skeletal muscle health” https://www.nmdpharma.com/board daily 0.75 2026-03-24 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/e4f29f5f-bee4-4947-8fac-878d71261088/231026_Mike-Heffernan_MMT_1000x.jpg Board - Mike Heffernan Chairman Mike was appointed Chairman of NMD Pharma in December of 2022, bringing with him 30 years of experience working in biopharmaceutical companies at both the development and commercial stages. He is a serial entrepreneur, most recently founding US-based oncology company Avenge Bio where he serves as the Chairman and CEO. He also founded, Collegium Pharmaceutical where he was the CEO until June 2018 and it currently the Chairman. Since launching his career at Eli Lilly and Company, Mike has held a number of leadership roles. He was the CEO and founder of the dermatology company Precision Dermatology which was sold to Valeant in 2014. Mike was also the CEO of Clinical Studies Ltd., a company sold to PhyMatrix Corp. in 1997. Mike is a registered pharmacist, holding a B.Sc. in Pharmacy from the University of Connecticut. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/65e3c7de-3547-4027-9519-4548b5ad12f9/Sabine+Dandiguian_500x500.jpg Board - Sabine Dandiguian Non-executive director Sabine Dandiguian is Managing Partner at Jeito Capital and has over 30 years of experience in the pharmaceutical and medical devices industry. She serves on the Boards of SparingVision, Pulmocide and NMD Pharma as a representative of Jeito. Prior to Jeito, she spent 20 years at Johnson & Johnson, notably becoming President of France at Janssen, then Managing Director of European emerging countries. Sabine has been recognized as Chevalier de l’Ordre du Mérite, Chevalier de la Légion d’Honneur and is a member of the « Assemblée des 100 » of Institut Pasteur. She has been a member of W.I.T.H. (Women Innovating Together in Healthcare) association since its creation. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/445fe84b-9949-407c-9f55-ff452abcb5f8/Christian+E.+Elling_500x500.jpg Board - Christian E. Elling Non-executive director Christian joined Lundbeckfonden in 2012 and is the managing partner of Lundbeckfonden BioCapital, the evergreen biotech investment unit of Lundbeckfonden and part of the leadership team of Lundbeckfonden. Christian applies more than 20 years of experience across drug development, biotech and venture capital. He is the chairperson of the board of directors of SNIPR Biome and Cytoki Pharma and member of the board of directors of IO Biotech, NMD Pharma, Afyx Therapeutics. He was a co-founder, VP and CEO of 7TM Pharma. Christian holds a PhD in Pharmacology from the University of Copenhagen, Denmark. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/83d8f529-e3d6-482b-bffb-fbb4fa5b5809/Woman_2+copy.jpg Board - Anja Harmeier Non-executive director A more detailed profile of the board member will be provided here. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/81214344-2886-467d-bd5d-0ad43b82d9a9/Ivan-Burkov-HC.jpg Board - Ivan Burkov Non-executive director Ivan is a biotech investor with a multidisciplinary background spanning academia, pharma, startups, and venture capital. He joined Inkef in 2019 where he advanced to General Partner and is currently serving on the Boards of several biotech and medtech companies. Having spent 10 years in research, he transitioned to strategy and business development at Sanofi, evaluating opportunities to maximize top line growth in line with the business’s global strategy. Ivan completed an MBA at INSEAD, holds a PhD in Genetics and was awarded a Marie Sklodowska-Curie postdoctoral fellowship. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/7ab4b514-87f5-4013-9576-776c218b4414/250313_JoaoRibas_MMT_website_1000x.jpg Board - João Ribas Non-executive director João Ribas joined NMD Pharma’s Board in 2025 after serving just over a year as a Board Observer. João currently serves as a Principal at Novo Holdings, where he focuses on early-stage investments, venture creation, and the management of SeedLab, the firm’s wet lab space for new company creation. He also holds several board positions and has led investments in companies including Asgard Therapeutics, Booster Therapeutics, Orbis Medicines, and Tribune Therapeutics. In addition to his investment role, João serves as an interim executive at Booster Therapeutics. Previously, João was an investor at M Ventures where he was involved in the full investment lifecycle, from deal sourcing to due diligence. He has also founded new ventures in the U.S. and Europe, earning several entrepreneurial awards. João holds a Ph.D. in bioengineering from the University of Coimbra and conducted research at Harvard Medical School and Brigham and Women’s Hospital. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/2f591ea3-b11a-4d65-aca8-2957959ecb43/Jeremy+Springhorn_500x500.jpg Board - Jeremy Springhorn Non-executive director Dr. Springhorn joined NMD Pharma’s Board in 2019. He has been Chief Executive Officer of Nido Biosciences since April 2021. Prior to this Jeremy held various senior positions including Chief Business Officer of Syros Pharmaceuticals, Inc., and Partner at Flagship Pioneering, where he worked with the VentureLabs group working with companies in various strategic and corporate development capacities, creating next generation startups, and working with Flagship’s Corporate Limited Partners. Jeremy was also one of the original scientists at Alexion Pharmaceuticals, Inc. and was one of the inventors of the drug Soliris®. Jeremy started at Alexion in 1992 where he served in various leadership roles in R&D before switching to Business Development in 2006. Jeremy received his PhD from Louisiana State University Medical Center in New Orleans and his BA from Colby College, Maine. Dr. Springhorn currently serves on the Board of Directors for uniQure N.V., the Board of Advisors for Mythic Therapeutics and the Board of Visitors for Colby College. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/e335ba33-8453-4760-8f96-e35b5f60b0d2/Thomas+Holm+Pedersen_500x500.jpg Board - Thomas Holm Pedersen Chief Executive Officer Thomas co-founded NMD Pharma and has been CEO of the Company since its inception in 2015. During this time, NMD Pharma has transitioned from early a discovery-stage to clinical-stage company. He has led various financing rounds of the Company including raising one of the largest Series A investments in the sector in Europe in 2018. The scientific basis of NMD Pharma - utilizing ClC-1 as a novel target for restoring muscle function in neuromuscular disease - comes from the academic work conducted at Aarhus University by Thomas and colleagues. Thomas obtained his PhD from Aarhus University and completed two years of post-doctoral work at Cambridge University. As a scientist, Thomas focused on cellular electrophysiology and ion channel biophysics, developing novel methods to understand the function and regulation of ClC-1 in health and disease. He has published more than 40 high-ranking papers including in Science and PNAS. https://www.nmdpharma.com/management-team daily 0.75 2025-09-11 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/45657ece-74b9-4e8a-91ef-5730a8ec3ef7/Thomas+Holm+Pedersen_500x500.jpg Management team - Thomas Holm Pedersen Chief Executive Officer Thomas co-founded NMD Pharma and has been CEO of the Company since its inception in 2015. During this time, NMD Pharma has transitioned from early a discovery-stage to clinical-stage company. He has led various financing rounds of the Company including raising one of the largest Series A investments in the sector in Europe in 2018. The scientific basis of NMD Pharma - utilizing ClC-1 as a novel target for restoring muscle function in neuromuscular disease - comes from the academic work conducted at Aarhus University by Thomas and colleagues. Thomas obtained his PhD from Aarhus University and completed two years of post-doctoral work at Cambridge University. As a scientist, Thomas focused on cellular electrophysiology and ion channel biophysics, developing novel methods to understand the function and regulation of ClC-1 in health and disease. He has published more than 40 high-ranking papers including in Science and PNAS. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/708ecaab-d117-44ea-8008-adbe27b2b459/Thomas+Kongstad+Petersen_500x500.jpg Management team - Thomas Kongstad Petersen Chief Operating Officer Thomas joined NMD Pharma as Chief Operating Officer in September 2019. Thomas has more than 20 years’ experience in the pharmaceutical and biotech industry. Before he joined NMD Pharma, he was Vice President of Global Clinical Operations at LEO Pharma where he previously also held several senior leadership positions within Research, Preclinical Development and CMC. He has worked in all stages of drug discovery and development up to and beyond product approval within a broad range of therapeutic areas including autoimmune disorders, skin diseases, oncology, critical care, and neuromuscular diseases. In 2016, Thomas was appointed by the Minister of Business, Industry and Financial Affairs to join the Governmental Growth Team of Life Science, advising the Government on growing life science in Denmark. Thomas is also Chairman of the Danish public-private partnership Trial Nation, promoters of clinical research in Denmark, and Chairman of the board of Basic & Clinical Pharmacology & Toxicology (BCPT). Thomas is mentor in the Scion DTU Innovation Mentor teams at the Danish Technical University. Thomas received his Doctorate of Veterinary Medicine at Copenhagen University, where he also obtained his PhD in Clinical Pathology. He also spent time conducting research at the Baylor College of Medicine, Texas. Thomas has published more than 30 peer-reviewed papers and reviews. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/606c3a07-773a-4146-8620-7da2f5cd942a/250903_Ana+de+Vera_Beton_1000x.jpg Management team - Ana de Vera Chief Medical Officer Ana joined NMD Pharma as Chief Medical Officer in September 2025. Ana has over 20 years of expertise in drug development and commercialization and a proven track record in leading projects and development teams across multiple therapeutic modalities, development stages and disease areas, including neuromuscular diseases. Prior to joining NMD Pharma, Ana served as Head of Development and Deputy CMO at Santhera Pharmaceuticals, where she played a pivotal role in securing regulatory approvals in the US and Europe, followed by submissions in additional countries globally. She also provided key scientific and strategic support to the commercial, market access, and medical affairs functions, shaping successful launch and reimbursement strategies across multiple markets. Previously, Ana spent over 15 years at Novartis AG, where she led clinical development programs from Phase 2 clinical trials through to commercialization in neurology, immunology, dermatology. In addition, she oversaw the design and execution of clinical trials of bimagrumab, a monoclonal antibody designed to treat pathological muscle loss and weakness in inclusion body myositis and sarcopenia. She also brings experience in leading medical safety teams, providing scientific and strategic expertise to Cardio-Renal-Metabolic development programs as well as Due Diligence and Integration Teams across various disease areas. With over a decade of clinical experience in neurology, Ana is a certified neurologist in both Spain and Switzerland and holds an M.D. from Oviedo University. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/6277ba12-69c3-413e-b924-bcf5d9a6bf7d/231026_Dan_Brennan_MMT_1000x.jpg Management team - Dan Brennan Senior Vice President of Corporate and Commercial Strategy Dan joined NMD Pharma as Senior Vice President of Corporate and Commercial Strategy in June 2023. Dan has 25 years of strategic commercial experience in the pharmaceutical and biotech industries in a variety of large, medium and clinical stage global companies, many working to develop medications for rare neurological diseases. This includes multiple senior leadership roles in public companies, including Chief Commercial Officer at Catalyst Pharmaceuticals and Chief Operating Officer at Edge Therapeutics, where he was responsible for pre-commercialization and launch activities of the companies’ lead products targeting rare neurological conditions. Prior to this, Dan held several leadership positions at Lundbeck U.S., including Vice President and Group General Manager of Lundbeck’s U.S. Neurology Business Unit and Business Development group. Throughout his time in these positions, Lundbeck’s U.S. Neurology group launched four specialty orphan products achieving over tenfold growth in revenue during his tenure. He also served as Divisional Vice President and General Manager of the Hospital Business Unit at Abbott Laboratories and was at Eli Lilly and Company for ten years in multiple sales, marketing and new product development roles of increasing responsibility. He was recently a volunteer member of the Board of Directors for the Huntington’s Disease Society of America for 6 years and previously served on the boards of the Illinois Biotechnology Organization (iBIO), Alzheimer’s Association and CASA (Court Appointed Special Advocates). Dan received a B.A. degree from the University of Notre Dame and an MBA degree, with distinction, from the Kellogg Graduate School of Business at Northwestern University. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/dc5f9281-1524-4734-9c4a-f289fb6b2720/250521_Morten+Bull_BETON_1000x.jpg Management team - Morten Bull Senior Vice President, General Counsel and Head of People & Business Services Morten joined NMD Pharma as Senior Vice President, General Counsel and Head of People & Business Services in January 2024 Morten has 20 years of experience as in-house counsel across several industries and legal areas with a focus on pharmaceutical Research & Development. Before joining NMD Pharma, Morten served as executive director and global head of IP and R&D Legal of LEO Pharma, where he was part of the Legal and R&D leadership teams and business partner to the M&A group. He was responsible for the global legal advice on clinical development, preclinical and non-clinical research collaborations, and M&A and licensing activities relating to the pipeline. Prior to this, Morten held several legal and leadership roles at the Danish incumbent telecoms provider TDC (Now Nuuday and TDC NET) with legal responsibilities covering M&A, financing and company secretary leading to the re-IPO of the company and commercial roles within strategy and sales. Morten is an attorney-at-law with a masters degree from Copenhagen University and also holds a US Healthcare Compliance Certificate Program from the Seton Hall University School of Law. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/6973932e-1b99-4e32-80bb-07d61d12b594/240910_Peter_Kasten_MMT_website_1000x.png Management team - Peter Kasten Vice President of Finance and IT Peter joined NMD Pharma as Vice President of Finance and IT in August 2024. Peter has 15 years of finance and digital transformation experience in the pharmaceutical, logistics and consultancy industries. Before joining NMD Pharma, Peter held various senior leadership roles at Danske Fragtmænd, a leading Danish transport and logistics company, including as head of digitalisation, where he was part of the management team. He was responsible for the modernisation of last-mile logistics systems, implementing advanced technologies for package sorting and inventory management. Before his role at Danske Fragtmænd, Peter served as a Manager at EY (Ernst & Young), where he advised large organisations within financial operations. His consultancy work was complemented by a decade at Novo Nordisk, where he played key roles in overseeing laboratory expansions in the U.S., and implementing global financial processes within the R&D organisation. Peter holds an M.Sc. in Finance and a B.Sc. in Business and Economics from Aarhus University. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/49a5bcef-c620-4c87-ad5a-78d5740670c7/231026_Chloe_Arrowsmith_Jensen_MMT_1000x.jpg Management team - Chloe Arrowsmith Jensen Executive Assistant to Chief Executive Officer Chloe joined NMD Pharma as Executive Assistant to the Chief Executive Officer in January 2023, bringing over 17 years of experience in stakeholder management and business development. Prior to joining NMD, she was head of the newly established institutional relations programme at British Patient Capital, the UK’s largest domestic investor into UK venture capital and growth opportunities in the life sciences and technology sectors. As part of her responsibilities, Chloe also acted as senior lead for numerous firmwide ESG, diversity and inclusion and strategic projects. At NMD Pharma, Chloe works in close collaboration with Thomas Holm Pedersen, CEO, supporting and enabling the development and implementation of the Company’s strategy. She has also been appointed as NMD Pharma’s ESG lead and will be responsible for overseeing NMDs efforts going forwards. Chloe received her BA (Hons) degree from the University of Surrey and also holds qualifications from the Chartered Alternative Investment Association and an Investment Management Certificate. https://www.nmdpharma.com/founders daily 0.75 2022-08-07 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1622456372110-U29S196VQ88GV4KX6BG8/Founders_Ole_Nielsen_500x500.jpg Founders - Ole Bækgaard Nielsen Ole’s main research interest is the regulation of channels and transporters in skeletal muscles and its importance for muscle excitability and function. He has authored more than 70 publications which also include papers on integrated physiology. In 2008 he was appointed a Professor at the Department of Biomedicine, Aarhus University, where he led research that formed the basis of the activities at NMD Pharma. Ole has been a Scientific Advisor and Board member for a number of organisations including Rhinix ApS, Spirare ApS, Team Denmark, ‘Physiotherapeutic Specialist Team’, and the Danish University Extension, Aarhus. From 2014 to 2016, he served as Deputy Head of the Department of Biomedicine, Aarhus University with special responsibility for the departmental teaching of medical students. From 2016-2018 he was Chief Technology Officer in NMD. Currently he is the Head of Department for the Department of Public Health and part of the leadership of the Faculty of Health at Aarhus University. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1620735545364-DFEE9B8P60C14258DK2C/Founders_Claus_Olesen_500x500.jpg Founders - Claus Elsborg Olesen Dr. Claus Elsborg Olesen earned his PhD in Physiology and Biophysics from Aarhus University in 2008. As a scientist Claus has focused on the structural biology of membrane proteins and has published more than 40 papers, with first authorships in Nature and Science. He is serial entrepreneur having co-founded multiple life science companies, where he has led and participated in securing investments and financing of more than €75m (e.g. NMD Pharma, STipe Therapeutics and Initiator Pharma). He is currently the CEO of STipe Therapeutics (immune-oncology) & Initiator Pharma (CNS). Claus is a former professional sailor having competed in the Americas Cup representing Sweden in 2003 and participating in two Olympics representing Denmark in the Star Class. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/e335ba33-8453-4760-8f96-e35b5f60b0d2/Thomas+Holm+Pedersen_500x500.jpg Founders - Thomas Holm Pedersen Thomas has an academic background in skeletal muscle physiology and neuromuscular disease. He holds a PhD in Physiology from Aarhus University and completed two years of post-doctoral work at Cambridge University. Thomas has years of experience in cellular electrophysiology and has published more than 30 high-ranking papers including a first author paper in Science and several papers in The Journal of General Physiology. NMD Pharma was founded on scientific discoveries obtained in the Muscle Laboratory at Aarhus University in which Thomas holds a position as Associate Professor. https://www.nmdpharma.com/science daily 0.75 2026-03-24 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1621430695965-A497ECMAP4HSI4GCR3GN/Nervous+control+of+movement.png Science - The motor system that controls movement consists of the motor neurons and the muscles which they innervate (figure 1) https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/a149d976-f88a-4886-bc1e-2f6ddc00b5dd/Pre-Post-Synaptic-Dysfunction-with-cmpd_two.png Science - The specialized region of the muscle where the motor neuron communicates the activation signal is at the neuromuscular junction. This is a specialized synapse between a nerve and muscle. In neuromuscular diseases there are deficits in both the motor neuron side (pre-synaptic) and on the muscle side (post-synaptic) (figure 2) https://www.nmdpharma.com/neuromuscular-diseases daily 0.75 2026-03-24 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1622120473556-K6ADGHHO1IEIHC0YMT8G/Neuromuscular_junction.png Neuromuscular diseases https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1621431725164-A9KW5Y7B7WE71IWPFVUF/Pre-Post-Synaptic-Dysfunction-with-cmpd_1.png Neuromuscular diseases https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1621431747458-027HBEUQS0U3JZ3E5AKX/Pre-Post-Synaptic-Dysfunction-with-cmpd_2.png Neuromuscular diseases https://www.nmdpharma.com/find-your-job daily 0.75 2026-03-31 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/e47e7596-4ba7-44f3-88a6-f65903d69135/260320_Laboratory+Technician+Apprentice_LI.jpg https://www.nmdpharma.com/careers-test daily 0.75 2021-05-19 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1620832568990-7343G3HM7Q4AD962IA51/2021-03-08-NMD-3023_KLD_500x500.jpg Careers test - Kamilla Løhde Dybdahl Research Scientist https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1620976353179-6OQDMVXEIPEJMABPJAUV/2021-03-08-NMD-2964_TSG_500x500.jpg Careers test - Thomas Skjærlund Grønnebæk Clinical Trial Administrator https://www.nmdpharma.com/kamilla-kld daily 0.75 2021-10-15 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1634295003609-S8PHAI54TKRVXRARCTS8/2021-09-29-NMD8749_500x500.jpg Kamilla - Kamilla Løhde Dybdahl, Research Scientist I am Kamilla Løhde Dybdahl, a Research Scientist and part of the Team Screening research team at NMD Pharma. As part of my day-to-day role, I perform ex vivo experiments in electrophysiology, mainly drug screening, but also smaller key research projects. The rest of my time is spent on data analysis and writing reports or preparing presentations. I am also a member of the EHS (environmental health and safety) group. Before joining NMD, I received a bachelor’s degree in molecular medicine, and subsequently a Master of Science in Engineering, biotechnology/biomedical technology, from Aarhus University. This position at NMD Pharma is my first professional role. I completed my bachelor’s thesis with Dr. Thomas Holm Pedersen, CEO of NMD Pharma, as my supervisor, which provided me with experience in muscle physiology before I joined the NMD team. Aside from that, my educational background has provided me with a very broad skillset that I use every day carrying out my diverse work tasks. It’s not just my interest in the subject that excites me to come to work every day. I really like the diversity of the work we do day-to-day, and that a lot of what we do is explorative – I guess that’s the scientist in me talking. Biotech is so fast-paced and you need to learn as you go which means you learn a lot in a short space of time and develop your skills and responsibilities quite quickly. This is what makes the job so exciting and challenging. It is also motivating that our work might actually help people in the future and contribute to the scientific understanding of neuromuscular disease in general. The best part for me, however, is the people working here. We have a lovely open culture where we are always encouraged to ask questions and have exciting discussions, on both work and non-work-related topics. Everyone here is very welcoming and friendly. You can always ask questions and discuss projects with colleagues. People here are passionate about the company and work hard to make it succeed. The tight-knit team means a close relationship can be developed between management, leaders and team members, and there is always room to speak your mind. Additionally, humor is a big part of our working culture and we can be rather silly at times, which I love. We are a very social team and have enjoyed many events together, both professionally and non-professionally. https://www.nmdpharma.com/thomas-sg daily 0.75 2025-10-22 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1634557460088-NWO2HTPTON9XVMMMHLA6/2021-03-08-NMD-2964_TSG_500x500_NY.jpg ThomasSG - Thomas Skjærlund Grønnebæk, Principal Scientist My name is Thomas Skjærlund Grønnebæk and I am a principal scientist and part of the clinical development team at NMD Pharma. As part of my role, I support the Head of Clinical Operations and Chief Medical Officer with clinical project management activities and contribute to the oversight of the clinical studies sponsored by NMD Pharma. Because we are a small team, my tasks vary quite a lot which is great to learn the complexities of clinical research in the pharmaceutical industry. During my first four months at NMD Pharma, my tasks ranged from writing systematic reviews, filing of central trial documents, reviewing protocols, preparation of scientific presentations to coordinating ethics submissions and database coding with investigators at collaborating universities. My first major tasks have been to set up a trial master file for the company’s first Phase I/IIa clinical study and to help initiate observational studies with the aim to identify new potential target populations for NMD Pharma’s lead drug candidate NMD670. Prior to joining NMD Pharma, I completed a PhD in Skeletal Muscle Physiology at Aarhus University. During my studies, I was a project leader on three clinical studies focusing on muscle metabolic abnormalities in cardiovascular disease and exercise as a countermeasure. I authored/co-authored nine scientific publications and was a visiting PhD scholar at the Oklahoma Medical Research Foundation. I feel very privileged to be at a company where I can use my background in muscle physiology and clinical research to aid the development of innovative treatments for patients with neuromuscular disease. I am surrounded by leading experts in physiology, drug discovery and clinical research and it is a great environment for learning. From what I have experienced during my first four months, NMD Pharma is a company with great ambitions and with an open and welcoming atmosphere where sharing of knowledge and information across the various teams is actively encouraged. One thing I particularly appreciate is our monthly seminars with contributions from the different teams and updates on high level goals and milestones from the management team. /Dec. 2021 Since the interview has been conducted, Thomas has been promoted to Clinical Trial Manager. /April 2022 and later on to Principal Scientist /2025 https://www.nmdpharma.com/terms-of-use daily 0.75 2024-01-18 https://www.nmdpharma.com/new-page-1 daily 0.75 2021-06-10 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1623325985570-Y6PAIWCZJ7L7T2XYE5A8/LATEST-UPDATE_2.png Home Clinical Trial - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.nmdpharma.com/clinical-trial-of-nmd670 daily 0.75 2022-01-13 https://www.nmdpharma.com/pipeline-test daily 0.75 2021-08-04 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1628074976207-1UYTP4ZGTTWO1T0R85H3/Pipeline_plain_1000x.jpg Pipeline - test https://www.nmdpharma.com/science-test daily 0.75 2021-08-06 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1628238787889-VQIIAHW5HM9UY5ALX40L/Nervous+control+of+movement.png Science - test - The motor system that controls movement consists of the motor neurons and the muscles which they innervate (figure 1) https://www.nmdpharma.com/scientific-publications-test daily 0.75 2021-08-04 https://www.nmdpharma.com/neuromuscular-diseases-test2 daily 0.75 2021-08-06 https://www.nmdpharma.com/press-releases daily 0.75 2024-06-07 https://www.nmdpharma.com/other-news daily 0.75 2025-09-11 https://www.nmdpharma.com/patient-insights daily 0.75 2026-03-24 https://www.nmdpharma.com/scientific-publications daily 0.75 2024-12-20 https://www.nmdpharma.com/scientific-publications-1 daily 0.75 2021-08-30 https://www.nmdpharma.com/trineruby daily 0.75 2021-11-12 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/6b5f9a64-1cee-49ad-bacd-4009e1aa2428/2021-09-20-NMD2223_TR_500x500.jpg TrineRuby - Trine Ruby, Director of Quality Assurance My name is Trine Ruby and I am Director of Quality Assurance (QA) at NMD Pharma. My day-to-day role is in Quality Assurance (QA) and I am part of the Operations team. I work with colleagues across the company, focused on developing our Quality Management System (QMS). As NMD is expanding into more regulated areas of drug development there are several regulatory requirements including the generic good practice (GXP) regulations our work must adhere to, to ensure participants in clinical trials and consumers of medicinal products are protected. Our drug development work will form the basis of regulatory submissions of novel treatments for neuromuscular disorders and must therefore fulfill these regulatory requirements. In addition, the QMS will ensure more standardized and effective business processes. Besides working with the QMS, I am responsible for ensuring that relevant vendors are audited, and I am involved in collaborating with our vendors and internal vendor managers to ensure that the right level of quality is supplied. In addition, I am always available for any compliance questions from colleagues. I completed an MSc. in Pharmaceutical Sciences plus a Ph.D. in neuropharmacology, where I investigated the mnemonic deficits in an animal model of schizophrenia. The Ph.D. was co-funded by the University of Copenhagen and H. Lundbeck A/S and included a stay in the UK working at the University of Bradford. After finalizing my Ph.D., I moved to Singapore and joined Takeda as a research scientist. When I moved back to Denmark I joined Novo Nordisk in the Clinical Supplies department, where I worked according to Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP), which is where my interest in compliance started. This led me to a position as a Qualified Person (QP) at Fertin Pharma and a strong GMP focus. It was a combination of several factors that drew me to NMD. The combination of responsibility for the quality direction of the company, and the fact that I get to develop my skills in Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) while working for a company that strives to improve the quality of life for people with large unmet medical needs. I am proud to say that I am working for NMD and I am proud of our vision. I like working here because there is a feeling that we are all in this together and we all strive to do our best. In addition, the management makes an effort to ensure that knowledge is shared throughout the company, whether it is information about the latest research, status on the non-clinical or clinical development, or status of investments. The culture at NMD is very positive and enthusiastic. As a new member of the NMD team it is my experience that everyone is happy to ask and answer questions and talk openly about their area of work. https://www.nmdpharma.com/privacy-policy daily 0.75 2024-01-18 https://www.nmdpharma.com/cookie-policy daily 0.75 2024-01-18 https://www.nmdpharma.com/values daily 0.75 2022-01-19 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1607694583486-2PQT0LQ193RL7MCB6DX4/20140228_Trade+151_0046.jpg Patient Spotlight https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1637321846640-UY8G65KM5IFZ4QREYT1F/Berit+Billede.jpg Patient Spotlight https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1607694583486-2PQT0LQ193RL7MCB6DX4/20140228_Trade+151_0046.jpg Patient Spotlight https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1637323532150-HMTR1FKKXKK5176ZHTZP/Berit+Billede.jpg Patient Spotlight https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/7a02c476-d8fd-4f08-bdee-f901c28b64ec/Berit+Billede.jpg Patient Spotlight - “Whatever it is, the way you tell your story online can make all the difference.” Berit Stagstrup, CMT Patient Berit Stagstrup, CMT Patient Berit Stagstrup, CMT Patient — Berit Stagstrup, CMT Patient https://www.nmdpharma.com/values-2 daily 0.75 2022-05-18 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1651744425965-8OP9CXB78MK6CZ4VD7RX/Values_WEB_Passionate+about+Movement.jpg Vision Mission Values https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1651744454987-128RQQ4WSGZ516BOSVLB/Values_WEB_Innovate+to+Evolve.jpg Vision Mission Values https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1651744468813-2X3VX3GTACRW1L479IWB/Values_WEB_Inspired+by+Resilience.jpg Vision Mission Values https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1651744483722-JASAOZJ7WR3FO2IE48NJ/Values_WEB_Support+and+Challenge.jpg Vision Mission Values https://www.nmdpharma.com/background daily 0.75 2021-12-16 https://www.nmdpharma.com/our-team daily 0.75 2026-03-27 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652649628074-R5KNHNGYD0BRMN3STKL0/220510_Jeanette_Jeppesen_Morgen_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652649877724-HI2WKCR3HA9RHYY2C29W/220510_Anders_Findsen_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652649931063-MMKVRF7JWIZDYNE89BNL/220510_Nete_Huus_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652650206143-TXWHXL9YE0K6Z4I0EIJX/220510_Jeppe_Blichfeldt_Winther_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652650258678-YV3SNDHY2EO31SN4TQEU/220510_Marianne_Gerberg_Skals_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652650297274-IQJAYXKV581S77ZAQFNK/220510_Kamilla_L%C3%B8hde_Dybdahl_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652650327526-VG8E6DA5K2V0J8F1XDIM/220510_Peter_Bentsen_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652650421534-II0ZWQI9JTJHZ7D7N88V/220510_Nicole_Nicolajsen_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652650513949-X8982YHL80R9GM2FMJ17/220510_Trine_B%C3%B6enche_S%C3%B8rensen_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652650747455-6AK7Y3IY2766FS1CJEC0/220510_Michael_Voldsgaard_Clausen_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652650932954-F4SW3FQKADC7U1ID0LFA/220510_Stine_Krag_Brunvold_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1652651735987-QA0PZQ5IFCE45R98Z4NY/220510_Martin_Broch-Lips_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1654169157098-T87PZ53RY3XKMLCKTZ0J/220510_Tina+Klitte+Holmstr%C3%B8m+Lohmann_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1654169243361-3F4WSF03J0MXH4JOI0DR/220510_Thomas+Skj%C3%A6rlund+Gr%C3%B8nneb%C3%A6k_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1654169440842-LDQQD784SQKBRDWC1H3H/220510_Pernille+Bogetofte+Thomasen_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1654169796112-SI1BRYMTLGK7U0FOS364/220510_Dorte+Olsson_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1654680475024-8ZTGTJ1UV7KWX8B8A316/220510_Vibeke+Uhre_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/e807889c-6948-413c-8699-46af85ee1e6f/230425_Katja_Krustrup_Pedersen_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/7a7196ba-b6b5-457d-ad3f-48ef7977bbcf/230425_Niels_Chr.+Felumb_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/6e48c2d4-5a7a-4b0b-9569-a41839c29983/230425_Thomas_Breuer_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1031cf59-4e57-4e6e-ba7c-307d76a4e052/230425_Caitlin_500x500.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/7dfb8573-4563-4e6b-b9d4-223c03a3baf1/221004_Jesper+Emil+Jakobsgaard_500x500_2.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/5d24b126-e20a-4738-94b4-d1158aab2d1d/221004_Anette+Kj%C3%A6r+Petersen_500x500_2.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1febd175-b009-4554-8374-0816e0240930/221004_Beatriz+Sevilla-Jensen_500x500_2.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/3d7175b7-0353-4534-a364-876a7a88cfb8/231026_Dorthe_Bach_Toft_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/130e7bfe-ce2e-4b56-b87a-6163ced26e12/231026_Vera_Kiyasova_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/f6597e7c-f1f3-48b1-85fd-b01d7c074646/231026_Nikolas_Kelly_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/e7217b96-5e5f-45cc-8077-942298f6a24d/240910_Morten_Dahl_S%C3%B8rensen_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/0c27a5a3-6361-4458-8b23-127222ca920f/240910_Cecilie_Kirkeby_Skeby_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/a893ca9d-6753-4750-84f6-bf6a0b8e47c6/240910_Mette_Jepsen_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/3951636d-14b0-4acc-8e1d-55cae0aa61e6/240910_Henriette_Tobiesen_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/c5113b88-b6a4-4d0d-affd-c7c2522c2413/240910_Karen_Rogvu_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1e989b88-4e3a-4682-8d9f-cd57c541adab/240910_Cecilia_Sparr_Eskilsson_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/176c2614-369c-47e2-85b3-9b56bf07a5bd/240910_Signe_Rode_Andreasen_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/19d47395-68b0-4053-8f9b-856c5de8f5a8/241121_Maja+Nielsen_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/728f5b7d-5ff3-4a7b-b74c-065952fd9002/241121_Karen+Hue_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/b8fe9f49-709d-423a-924d-f63160287603/241121_Teresa+Gidaro_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/734dc368-e632-4393-b900-3cbacc99a52c/250521_Alok+Singh_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1bf1aff7-a0ef-40c6-8b3b-704239ab515a/250521_Michael+Dyrgaard+Lundov_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/0bb62cd5-823a-4f57-9a16-e132146108f4/250521_Hang+Nguyen+Nielsen_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/6eba8ecb-93fd-45c6-9e42-1866373b859a/250521_Lone+Lund_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/e39b6daa-139e-4882-b104-22366d39655e/250521_Karen+Wibe+Enevoldsen_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/46c5f5ea-8273-409e-bb1d-b8708b98fab5/250521_Laurane+Mackels_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/83d8f529-e3d6-482b-bffb-fbb4fa5b5809/Woman_2+copy.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/e2f7dee3-78e8-44c0-8769-d4b706db01dc/260311_Anne+Sofie_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1c7f960d-e38b-4844-91cd-8eb2174474f8/260311_Marlene+Vestergaard_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1dbfce45-ce60-4a4f-b3fe-5f2f528e44a8/260311_Camilla+Tvede+Schytz_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/73ed764c-41e7-4504-88eb-e9edd09810f2/260311_Jurgen+Brem_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/82ab1fbc-92a6-4833-9c80-d40a9def33b3/260311_Joanna+Krzynowek_1000x.jpg Our team https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/141c898a-6228-4b95-aa6d-823b9e624d27/251117_Aldemar-Degroot_1000x.jpg Our team https://www.nmdpharma.com/tina daily 0.75 2022-04-01 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/54ae2de3-ce6a-49de-a29a-41c1e6cdf297/Tina_Lohmann_500x500.jpg TinaHL Tina Lohmann, Veterinary Nurse and Laboratory Technician My name is Tina Lohmann and I work as a Veterinary Nurse and Laboratory Technician at NMD Pharma, where I conduct research within the Pharmacology Team. In this team, we work with compounds that have passed the required qualification for further investigation. My primary role at NMD Pharma is to perform pre-clinical experiments and to deliver high-quality data, and it has been quite an exciting journey to be part of developing and expanding our pharmacological models over the last six years. I am also part of the Research Operation Group where we continuously work on guidance documents, equipment registration, laboratory volume-up purchase and shipping. I am educated and trained as a veterinarian nurse and a laboratory technician and have worked as both at veterinary clinics/hospitals and at analytical laboratories. Prior to NMD Pharma I worked for 10 years at a private pre-clinical contract research organisation and gathered lots of experience with multiple types of in vivo studies. During those years I developed my skills across various laboratory procedures, which benefits me in my role today at NMD Pharma. Coming to NMD Pharma in 2016 was exciting and a new world to me. It was great to join a group of people that were so dedicated and passionate about their research. It was, and still is, very motivating to work with muscle physiology and neuromuscular disorders and it feels important and meaningful every day. I like that we all contribute to the overall goal with our different competencies, and we respect each other for that. Everyone here is helpful and you can always be sure to receive an answer to any question asked. I enjoy working at NMD Pharma because there is a friendly and collaborative atmosphere, where everybody feels responsible for the work that we do. Even though we are very ambitious and serious about our work, we all strive to maintain a “good spirit.” I think NMD Pharma has put in the effort to maintain its culture even though we have grown quickly from a few people to almost 30 employees today. It is important that a company sets good values and tries to live by them and at NMD Pharma we all try to do exactly that. https://www.nmdpharma.com/events daily 0.75 2026-03-24 https://www.nmdpharma.com/martinskov daily 0.75 2025-10-22 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/8e15c94d-4552-4e8b-8f81-ad263fb0b9b7/221019_Martin_Skov_500x500.jpg https://www.nmdpharma.com/marianne-skals daily 0.75 2025-10-22 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/9afa5fb0-2309-4c4f-8335-2928260f6a31/230103_Marianne_Skals_alt_500x500.jpg https://www.nmdpharma.com/jeppebw daily 0.75 2023-03-15 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/d286b8fe-0301-4bc3-9663-8a035ca5d1ef/230315_Jeppe-Blichfeldt-Winther_500x500.jpg https://www.nmdpharma.com/science-1 daily 0.75 2023-08-04 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1621430695965-A497ECMAP4HSI4GCR3GN/Nervous+control+of+movement.png Science (Copy) - The motor system that controls movement consists of the motor neurons and the muscles which they innervate (figure 1) https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1621430695965-A497ECMAP4HSI4GCR3GN/Nervous+control+of+movement.png Science (Copy) - The motor system that controls movement consists of the motor neurons and the muscles which they innervate (figure 1) https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1621513192824-XURZUI5RDYR0GRDIO6VH/Pre-Post-Synaptic-Dysfunction-with-cmpd_two.png Science (Copy) - The specialized region of the muscle where the motor neuron communicates the activation signal is at the neuromuscular junction. This is a specialized synapse between a nerve and muscle. In neuromuscular diseases there are deficits in both the motor neuron side (pre-synaptic) and on the muscle side (post-synaptic) (figure 2) https://www.nmdpharma.com/contact-form-test daily 0.75 2024-01-26 https://www.nmdpharma.com/katja-kp daily 0.75 2025-10-22 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/55611caf-9e94-4434-8098-20aed1c05c7f/240312_Katja_Krustrup_Pedersen_1000x.jpg https://www.nmdpharma.com/michaelvc daily 0.75 2025-10-22 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/bf6b306d-026c-447e-80d1-16024e57d87f/240807_Michael_4_500x500.jpg https://www.nmdpharma.com/us-expanded-access-policy daily 0.75 2025-09-26 https://www.nmdpharma.com/information-for-patients daily 0.75 2026-03-24 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/ffbf6e15-65e8-4394-afc6-eac5e20ad3bd/00_2025-05-21-NMD_MOLS-GRUPPE_small_.jpg https://www.nmdpharma.com/new-page-2 daily 0.75 2025-05-28 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1615977781772-1R7308IXRKPLLRHLQJ7V/2021-03-08-NMD-2759_TKP_hands_1000x750.jpg Copy__Home - Management team, board and founders Our team is comprised of experts and leaders from around the world dedicated to developing novel treatments to improve muscle function and quality of life of patients with neuromuscular disease. Learn more about the management team, board and founders https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/f10b8486-4471-4d09-9f63-68d8abb0529b/Pipeline_1000x750_V3.jpg Copy__Home - Pipeline We are working to develop novel small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels that can be applied to a large range of clinical indications and orphan human diseases. https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/5cfbfbf8-28d3-47fd-b910-6ce3921522be/EOY_Logo_TM.gif https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1da64318-7d12-40a7-9696-8788c64cf10c/IncubaSTARTUP2022.gif https://www.nmdpharma.com/myasthenia-gravis-1 daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/aba0cfaa-8370-4976-92f6-7350de128f8d/231110_Pills_100_200_300mg.jpg https://www.nmdpharma.com/spinal-muscular-atrophy daily 0.75 2026-03-24 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/d3316e5d-ab64-4437-ab1e-f5d415accd78/SMA_Man_Stairs_down.jpg https://www.nmdpharma.com/contact-form-step-2-patient daily 0.75 2025-06-10 https://www.nmdpharma.com/contact-form-step-1-patient daily 0.75 2025-06-10 https://www.nmdpharma.com/contact-form-step-3 daily 0.75 2025-06-10 https://www.nmdpharma.com/contact-1 daily 0.75 2025-06-10 https://www.nmdpharma.com/spinal-muscular-atrophy-1 daily 0.75 2025-06-20 https://www.nmdpharma.com/spinal-muscular-atrophy-2 daily 0.75 2026-03-24 https://www.nmdpharma.com/clinical-trials-and-patients-1 daily 0.75 2025-06-20 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/5f51d141-ec8e-4161-ab75-f36a938ab9b4/Rectangle+16.jpg https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/fd2c36d1-39c7-4ca7-a6f4-783cd349c48b/Rectangle+18.jpg https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1746718334505-KT3585MMAYV1AK79935U/unsplash-image-FiIgXyC3t84.jpg https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/1746718236813-2I5HCPZIW3M17PFDNX0E/unsplash-image-eHOZjZEx7u8.jpg https://www.nmdpharma.com/spinal-muscular-atrophy-3 daily 0.75 2025-06-20 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/4b2e9fd5-c4d5-4d1d-bf65-26a5dacc3856/2544221657_b.jpg https://www.nmdpharma.com/myasthenia-gravis daily 0.75 2026-03-24 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/12ef21f8-0210-4930-b7db-f4f94d452d9c/MG_woman.jpg https://www.nmdpharma.com/t-e-s-t-1 daily 0.75 2025-07-04 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/d6069999-a012-4166-97ca-493710b6357b/Aro+Ha_0387.jpg https://www.nmdpharma.com/t-e-s-t-2 daily 0.75 2025-07-04 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1589846853455-RXDWCTPVKAHJKI4LTGEL/20140301_Trade-151_0124-copy.jpg T e s t 2 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1589846852937-89YBE3YXOTJFZ5X00LG6/20140228_Trade+151_0046.jpg T e s t 2 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1589846852077-R8DLR086HTER261C26DW/Aro+Ha_0428.jpg T e s t 2 https://www.nmdpharma.com/t-e-s-t-3 daily 0.75 2025-07-04 https://www.nmdpharma.com/charcot-marie-tooth-disease daily 0.75 2026-03-26 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/2cfb2473-c039-4c5d-b8e9-0a8ea51c2752/01_CMT.jpg https://www.nmdpharma.com/spinal-muscular-atrophy-4 daily 0.75 2026-03-26 https://images.squarespace-cdn.com/content/v1/60015fa94b905b61b3febe42/d3316e5d-ab64-4437-ab1e-f5d415accd78/SMA_Man_Stairs_down.jpg